Oppenheimer Begins Coverage on InflaRx (NASDAQ:IFRX)

Investment analysts at Oppenheimer began coverage on shares of InflaRx (NASDAQ:IFRX) in a research note issued to investors on Thursday,Benzinga reports. The firm set an “outperform” rating and a $6.00 price target on the stock. Oppenheimer’s target price would indicate a potential upside of 272.67% from the stock’s previous close.

IFRX has been the subject of several other reports. Guggenheim upped their price target on shares of InflaRx from $7.00 to $10.00 and gave the stock a “buy” rating in a report on Wednesday, March 26th. HC Wainwright reiterated a “buy” rating and issued a $8.00 target price on shares of InflaRx in a research report on Friday, March 21st. Finally, Cantor Fitzgerald assumed coverage on InflaRx in a report on Tuesday, April 29th. They set an “overweight” rating and a $10.00 price target on the stock.

InflaRx Stock Performance

Shares of IFRX opened at $1.61 on Thursday. InflaRx has a 52-week low of $0.82 and a 52-week high of $2.82. The firm has a market cap of $108.08 million, a price-to-earnings ratio of -1.49 and a beta of 1.57. The business’s fifty day moving average is $1.23 and its 200-day moving average is $1.82.

InflaRx (NASDAQ:IFRX) last issued its earnings results on Wednesday, May 7th. The company reported ($0.14) EPS for the quarter, topping the consensus estimate of ($0.18) by $0.04. InflaRx had a negative return on equity of 65.98% and a negative net margin of 33,362.70%. The firm had revenue of $0.03 million during the quarter, compared to the consensus estimate of $0.03 million. As a group, research analysts forecast that InflaRx will post -1.04 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of the stock. Raymond James Financial Inc. acquired a new stake in shares of InflaRx in the fourth quarter valued at about $1,576,000. Commonwealth Equity Services LLC boosted its holdings in InflaRx by 20.5% in the fourth quarter. Commonwealth Equity Services LLC now owns 111,500 shares of the company’s stock valued at $275,000 after acquiring an additional 19,000 shares during the last quarter. Geode Capital Management LLC increased its position in InflaRx by 32.8% during the 4th quarter. Geode Capital Management LLC now owns 48,136 shares of the company’s stock valued at $119,000 after purchasing an additional 11,900 shares during the period. Walleye Capital LLC bought a new position in InflaRx during the 4th quarter worth approximately $51,000. Finally, Two Sigma Securities LLC bought a new position in InflaRx during the 4th quarter worth approximately $28,000. 42.39% of the stock is owned by institutional investors.

About InflaRx

InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States. The company's C5a is an inflammatory mediator that is involved in the progression of a variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody, which completed the Phase III clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; for the treatment of anti-neutrophil cytoplasm antibody associated vasculitis, a rare and life-threatening autoimmune disease that is in Phase II trial; to treat pyoderma gangraenosum, a chronic inflammatory skin disorder that is in Phase IIa exploratory study; and for the treatment of PD-1/PD-L1 inhibitor resistant/refractory locally advanced or metastatic cutaneous squamous cell carcinoma that is in Phase II clinical development stage.